Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.6
3.6
Journals
Diagnostics
Special Issues
Epigenetic Biomarkers and Diagnostics
share announcement

Epigenetic Biomarkers and Diagnostics

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".

Deadline for manuscript submissions: closed (30 September 2022) | Viewed by 1694

Special Issue Editor

Dr. Monika Ulamec

E-Mail Website
Guest Editor
Ljudevit Jurak Clinical Department of Pathology and Cytology, University Clinical Hospital Center Sestre Milosrdnice, 10000 Zagreb, Croatia
Interests: renal oncocytoma; renal cell carcinoma; chromosome 7; gene fusion; melan A; testicular germ cell tumor; seminoma; embryonal carcinoma; cell biology; immunohistochemistry; tumors; apoptosis; cancer; immunology; cancer diagnostics; cancer biology; cancer biomarkers; cell culture

Special Issue Information

Dear Colleagues,

Technological achievements and new opportunities in medicine are setting our goals toward minimally invasive procedures while maintaining maximum quality of life in cancer patients. More precise targeted diagnostic markers are needed to make this possible. Huge progress has been made in understanding of tumor growth, biology, and behavior in the field of urogenital, lung, colorectal, and breast cancer. Epigenetic alterations in tumor cells, as well as in tumor microenvironments, play an important role in the pathogenesis of the cancer and are reflecting post-genetic changes related to different lifestyles and conditions. DNA methylation, histone modifications, micro-RNA, and other noncoding RNA are most researched epigenetic markers (epimark). Epigenetic signatures are explored in the tumor tissue, as well as in the liquid biopsy which is giving us a possibility to find and research most aggressive clones of cancer knowing that heterogeneity is one of the cancer hallmarks. Epimarks are stable and accessible with the possibility to follow the changes during the time. A high number of candidates for epimarks are continuously proposed and it is crucial to validate them properly with the finally good balanced assays giving us the best possible diagnostic accuracy. A critical approach to this field is of most importance. Special Issue would like to summarize the state of the cancer epimark field by showcasing the best research from around the world. We are flexible about the length and format of articles. We hope you share our interest in this fascinating area and can join us with your research.

Dr. Monika Ulamec
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • epigenetic
  • cancer biomarker
  • DNA methylation
  • histone modification
  • miRNA
  • cell free DNA
  • genome DNA

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

15 pages, 3815 KiB  
Article
Bone-Metabolism-Related Serum microRNAs to Diagnose Osteoporosis in Middle-Aged and Elderly Women
by Sheng-Li Zhao, Zhen-Xing Wen, Xiao-Yi Mo, Xiao-Yan Zhang, Hao-Nan Li, Wing-Hoi Cheung, Dan Fu, Shi-Hong Zhang, Yong Wan and Bai-Ling Chen
Diagnostics 2022, 12(11), 2872; https://doi.org/10.3390/diagnostics12112872 - 19 Nov 2022
Cited by 5 | Viewed by 1406
Abstract
Objective: Postmenopausal osteoporosis (PMOP), a chronic systemic metabolic disease prevalent in middle-aged and elderly women, heavily relies on bone mineral density (BMD) measurement as the diagnostic indicator. In this study, we investigated serum microRNAs (miRNAs) as a possible screening tool for PMOP. [...] Read more.
Objective: Postmenopausal osteoporosis (PMOP), a chronic systemic metabolic disease prevalent in middle-aged and elderly women, heavily relies on bone mineral density (BMD) measurement as the diagnostic indicator. In this study, we investigated serum microRNAs (miRNAs) as a possible screening tool for PMOP. Methods: This investigation recruited 83 eligible participants from 795 community-dwelling postmenopausal women between June 2020 and August 2021. The miRNA expression profiles in the serum of PMOP patients were evaluated via miRNA microarray (six PMOP patients and four postmenopausal women without osteoporosis (n-PMOP) as controls). Subsequently, results were verified in independent sample sets (47 PMOP patients and 26 n-PMOP controls) using quantitative real-time PCR. In addition, the target genes and main functions of the differentially expressed miRNAs were explored by bioinformatics analysis. Results: Four highly expressed miRNAs in the serum of patients (hsa-miR-144-5p, hsa-miR-506-3p, hsa-miR-8068, and hsa-miR-6851-3p) showed acceptable disease-independent discrimination performance (area under the curve range: 0.747–0.902) in the training set and verification set, outperforming traditional bone turnover markers. Among four key miRNAs, hsa-miR-144-5p is the only one that can simultaneously predict changes in BMD in lumbar spine 1–4, total hip, and femoral neck (β = −0.265, p = 0.022; β = −0.301, p = 0.005; and β = −0.324, p = 0.003, respectively). Bioinformatics analysis suggested that the differentially expressed miRNAs were targeted mainly to YY1, VIM, and YWHAE genes, which are extensively involved in bone metabolism processes. Conclusions: Bone-metabolism-related serum miRNAs, such as hsa-miR-144-5p, hsa-miR-506-3p, hsa-miR-8068, and hsa-miR-6851-3p, can be used as novel biomarkers for PMOP diagnosis independent of radiological findings and traditional bone turnover markers. Further study of these miRNAs and their target genes may provide new insights into the epigenetic regulatory mechanisms of the onset and progression of the disease. Full article
(This article belongs to the Special Issue Epigenetic Biomarkers and Diagnostics)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop